Advertisement
UK markets close in 7 hours 12 minutes
  • FTSE 100

    8,057.01
    +33.14 (+0.41%)
     
  • FTSE 250

    19,693.63
    +94.24 (+0.48%)
     
  • AIM

    752.25
    +3.07 (+0.41%)
     
  • GBP/EUR

    1.1573
    -0.0016 (-0.14%)
     
  • GBP/USD

    1.2362
    +0.0012 (+0.10%)
     
  • Bitcoin GBP

    53,403.13
    -61.10 (-0.11%)
     
  • CMC Crypto 200

    1,393.70
    -21.06 (-1.49%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    82.70
    +0.80 (+0.98%)
     
  • GOLD FUTURES

    2,320.30
    -26.10 (-1.11%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,823.04
    +311.35 (+1.89%)
     
  • DAX

    17,983.48
    +122.68 (+0.69%)
     
  • CAC 40

    8,060.88
    +20.52 (+0.26%)
     

The Key Challenges Teva Pharmaceutical Is Facing

The Key Challenges Teva Pharmaceutical Is Facing

Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) announced a restructuring plan to recuperate sales. Its stock has had a bull run since the announcement, rising 44.5% since the company’s weak earnings results for fiscal 3Q17 on November 2, 2017.